Abstract
Several inflammatory and immunological factors have been established as important contributors to atherogenesis. Among these, oxidized low-density lipoprotein (oxLDL) play a central role in the initiation and progression of atherosclerotic lesions. In atherosclerotic lesions, oxLDL was also found to co-localize with β2-glycoprotein I (β2-GPI). Immunoglobulin (Ig)G autoantibodies against β2-GPI complexed with oxLDL are pro-atherogenic because they increase uptake of the complexes by macrophages. In contrast, IgM natural anti-oxLDL antibodies derived from atherosclerosis-prone apolipoprotein E (ApoE) deficient mice reduced incidence of atherosclerosis. Such anti-oxLDL antibodies have been found in humans, and the accumulating evidences seem to support the idea that anti-oxLDL antibodies have a protective role for atherogenesis. Intravenous immunoglobulins (IVIgs) contain natural anti-oxLDL antibodies and infusion of IVIg into ApoE-deficient mice has been reported to decrease atheerosclerosis. The anti-atherogenic property of IVIg may be derived from non-antigen-specific antibody binding to FCγ receptors, which blocks foam cell formation of macrophages. Several other possible mechanisms are also discussed.
Similar content being viewed by others
References
Steinbrecher, U. P., Parthasarathy, S., Leake, D. S., et al. (1984), Proc Natl Acad Sci USA 81, 3883–3887.
Steinberg, D., Parthasarathy, S., Carew, T. E., et al. (1989), N Engl J Med 320, 915–924.
Steinberg, D. (1997), J Biol Chem. 272, 20,963–20,966.
Hammer, A., Kager, G., Dohr, G., et al. (1995), Arterioscler Thromb Vasc Biol 15, 704–713.
George, J., Harats, D., Gilburd, B., et al. (1999), Circulation 99, 2227–2230.
Horkko, S., Binder, C. J., Shaw, P. X., et al. (2000), Free Radic Biol Med 28, 1771–1779.
Shoenfeld, Y., Wu, R., Dearing, L.D., and Matsuura, E. (2004), Circulation 110, 2552–2558.
Yla-Herttuala, S., Palinski, W., Butler, S.W., et al. (1994), Arterioscler Thromb Vasc Biol 14, 32–40.
Salonen, J. T., Yla-Herttuala, S., Yamamoto R., et al. (1992), Lancet 339, 883–887.
Erkkila, A. T., Narvanen, O., Lehto, S., et al. (2000), Arterioscler Thromb Vasc Biol 20, 204–209.
Hulthe, J., Wiklund, O., Hurt-Camejo, E., et al. (2001), Arterioscler Thromb Vasc Biol 21, 269–274.
Vaarala, O., Alfthan, G., Jauhiainen, M., et al. (1993), Lancet 341, 923–925.
Tinahones, F. J., Cuadrado, M. J., Khamashta, M. A., et al. (1998), Brit J Rheumatol 37, 746–749.
Romero, F. I., Amengual, O., Atsumi, T., et al. (1998), Brit J Rheumatol 37, 883–888.
Kobayashi, K., Kishi, M., Atsumi, T., et al. (2003), J Lipid Res 44, 716–726.
Kasahara, J., Kobayashi, K., Maeshima, Y., et al. (2004), Nephron Clin Pract 98, c15-c24.
Hasunuma, Y., Matsuura, E., Makita, Z., et al. (1997), Clin Exp Immunol 107, 569–573.
Kobayashi, K., Matsuura, E., Liu, Q., et al. (2001), J. Lipid Res 42, 697–709.
Liu, Q., Kobayashi, K., Inagaki, J., et al. (2002), J Lipid Res 43, 1486–1495.
Chang, M. K., Bergmark, C., Laurila, A., et al. (1999), Proc Natl Acad Sci USA 96, 6353–6358.
Horkko, S., Bird, D. A., Miller, E., et al. (1999), J Clin Invest 103, 117–128.
Binder, C. J., Horkko, S., Dewan, A., et al. (2003), Nat Med 9, 736–743.
Rose, N. and Afanasyeva, M. (2003), Nat Med 9, 641–642.
Nicoletti, A., Kaveri, S., Caligiuri, G., et al. (1998), J Clin Invest 102, 910–918.
Kazatchkine, M. D. and Karveri, S. V. (2001), N Engl J Med 345, 747–755.
Wu, R., Shenfeld, S., Sherer, Y., et al. (2003) Autoimmun 36, 91–97.
Cushing, S. D., Berliner, J. A., Valente, A. J., et al. (1990), Proc Natl Acad Sci USA 87, 5134–5138.
Rajavashisth, T. B., Andalibi, A., Territo, M. C., et al. (1990), Nature 344, 254–257.
Nakata, A., Miyagawa, J., Yamashita, S., et al. (1996), Circulation 94, 2778–2786.
Frostegard, J., Wu, R., Haegerstrand, A., et al. (1993), Atherosclerosis 103, 213–219.
Mach, F., Schonbeck, U., Sukhova, G. K., et al. (1998), Nature 394, 200–203.
Steinberg, D. (2002), Nat Med 8, 1211–1217.
Bouma, B., de Groot, P. G., van den Elsen, J. M., et al. (1999), EMBO J 18, 5166–5174.
Lopez, D., Garcia-Valladares, I., Palafox-Sanchez, C., et al. (2004), Am J Clin Pathol 121, 426–436.
Lopez, D., Kobayashi, K., Merrill, J. T., et al. (2003), Clin Dev Immunol 10, 203–211.
Palinski, W., Horkko, S., Miller, E., et al. (1996), J Clin Invest 98, 800–814.
Shaw, P. X., Horkko, S., Chang, M. K., et al. (2000), J Clin Invest 105, 1731–1740.
Horkko, S., Bird, N. A., Miller, E., et al. (1999), J Clin Invest 103, 117–128.
Zhou, X., Caligiuri, G., Hamsten, A., et al. (2001), Arterioscler Thromb Vasc Biol 21, 108–114.
Caligiuri, G., Nicoletti, A, Poirier, B., et al. (2002), J Clin Invest 109, 745–753.
George J., Afek, A., Gilburd, B., et al. (1998), Atherosclerosis 138, 147–152.
Shoenfeld, Y., Haratz, D., George, J., et al. (2000), J Autoimmun 15, 199–202.
Yla-Herttuala, S., Palinski, W., Bulter, S. W., et al. (1994), Arterioscler Thromb Vasc Biol 14, 32–40.
Bergmark, C. K., Wu, R., de Faire, U., et al. (1995), Arterioscler Thromb Vasc Biol 15, 441–445.
Iughetti, L., Volta, C., Maggi, E., et al. (1999), Pediatr Res 45, 94–99.
Virella, G., Virella, I., Leman, R. B., et al. (1993), Int J Clin Lab Res 23, 95–101.
Wu, R., de Faire, U., Lemne, C., et al. (1999), Hypertension 33, 53–59.
Lopes-Virella, M. F., Virella, G., Orchard, T. J., et al. (1999), Clin Immunol 90, 165–172.
Shoji T., Nishizawa, Y., Fukumoto, M., et al. (2000), Atherosclerosis 148, 171–177.
Fukumoto, M., Shoji, T., Emoto, M., et al. (2000), Arterioscler Thromb Vasc Biol 20, 703–707.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Matsuura, E., Kobayashi, K., Inoue, K. et al. Intravenous immunoglobulin and atherosclerosis. Clinic Rev Allerg Immunol 29, 311–319 (2005). https://doi.org/10.1385/CRIAI:29:3:311
Issue Date:
DOI: https://doi.org/10.1385/CRIAI:29:3:311